{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:05Z","timestamp":1790840405391,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870104"],"award-info":[{"award-number":["81870104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870104"],"award-info":[{"award-number":["81870104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870104"],"award-info":[{"award-number":["81870104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-A-020"],"award-info":[{"award-number":["2020-I2M-C&T-A-020"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-B-090"],"award-info":[{"award-number":["2020-I2M-C&T-B-090"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-A-020"],"award-info":[{"award-number":["2020-I2M-C&T-A-020"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-B-090"],"award-info":[{"award-number":["2020-I2M-C&T-B-090"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-A-020"],"award-info":[{"award-number":["2020-I2M-C&T-A-020"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2020-I2M-C&T-B-090"],"award-info":[{"award-number":["2020-I2M-C&T-B-090"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fun"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We used data from 852 consecutive subjects with myelodysplastic neoplasms (MDS) diagnosed according to the 2016 (revised 4th) World Health Organization (WHO) criteria to evaluate the 2022 (5th) edition WHO classification of MDS. 30 subjects previously classified as MDS with an <jats:italic>NPM1<\/jats:italic> mutation were re-classified as acute myeloid leukaemia (AML). 9 subjects previously classified as MDS-U were re-classified to clonal cytopenia of undetermined significance (CCUS). The remaining 813 subjects were diagnosed as: MDS-5q (<jats:italic>N<\/jats:italic>\u2009=\u200911 [1%]), MDS-SF3B1 (<jats:italic>N<\/jats:italic>\u2009=\u200970 [9%]), MDS-biTP53 (<jats:italic>N<\/jats:italic>\u2009=\u200953 [7%]), MDS-LB (<jats:italic>N<\/jats:italic>\u2009=\u2009293 [36%]), MDS-h (<jats:italic>N<\/jats:italic>\u2009=\u200980 [10%]), MDS-IB1 (<jats:italic>N<\/jats:italic>\u2009=\u2009161 [20%]), MDS-IB2 (<jats:italic>N<\/jats:italic>\u2009=\u2009103 [13%]) and MDS-f (<jats:italic>N<\/jats:italic>\u2009=\u200942 [5%]) and MDS-biTP53 (<jats:italic>N<\/jats:italic>\u2009=\u200953 [7%]). 34 of these subjects came from the 53 (64%) MDS-biTP53 previously diagnosed as MDS-EB. Median survival of subjects classified as MDS using the WHO 2022 criteria was 45 months (95% Confidence Interval [CI], 34, 56 months). Subjects re-classified as MDS-biTP53 and MDS-f had significantly briefer median survivals\u00a0compared with other MDS sub-types (10 months, [8, 12 months] and 15 months [8, 23 months]). In conclusion, our analyses support the refinements made in the WHO 2022 proposal.<\/jats:p>","DOI":"10.1038\/s41375-022-01718-7","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T15:05:44Z","timestamp":1665587144000},"page":"2875-2882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms"],"prefix":"10.1038","volume":"36","author":[{"given":"Yudi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingye","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-4489","authenticated-orcid":false,"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"1718_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia."},{"key":"1718_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"1718_CR3","doi-asserted-by":"publisher","first-page":"73483","DOI":"10.18632\/oncotarget.19008","volume":"8","author":"P Valent","year":"2017","unstructured":"Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483\u2013500.","journal-title":"Oncotarget."},{"key":"1718_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood."},{"key":"1718_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:1399\u2013420.","journal-title":"NEJM Evid"},{"key":"1718_CR6","first-page":"259","volume":"32","author":"L Liu","year":"2011","unstructured":"Liu L, Cui W, Zhang H, Xu Z, Zhang F, Zheng Y, et al. Study on the implications of erythroblasts periodic acid-Schiff stain in myelodysplastic syndromes. Chin J Hematol. 2011;32:259\u201364.","journal-title":"Chin J Hematol"},{"key":"1718_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-016-0041-6","volume":"5","author":"G Feng","year":"2015","unstructured":"Feng G, Gale RP, Cui W, Cai W, Huang G, Xu Z, et al. A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol. 2015;5:12.","journal-title":"Exp Hematol Oncol"},{"key":"1718_CR8","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica."},{"key":"1718_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/leu.2012.30","volume":"26","author":"TM Westers","year":"2012","unstructured":"Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730\u201341.","journal-title":"Leukemia."},{"key":"1718_CR10","unstructured":"Shaffer LG, McGowan-Jordan J, Schmid M ISCN 2013: an international system for human cytogenetic nomenclature (2013). Karger Medical and Scientific Publishers, 2013."},{"key":"1718_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/gcc.22510","volume":"57","author":"B Li","year":"2018","unstructured":"Li B, Liu J, Jia Y, Wang J, Xu Z, Qin T, et al. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes, Chromosomes Cancer. 2018;57:80\u201388.","journal-title":"Genes, Chromosomes Cancer"},{"key":"1718_CR12","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1718_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, et al. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021;39:1223\u201333.","journal-title":"J Clin Oncol"},{"key":"1718_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.leukres.2017.02.008","volume":"57","author":"C Strupp","year":"2017","unstructured":"Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leuk Res. 2017;57:78\u201384.","journal-title":"Leuk Res"},{"key":"1718_CR15","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007;25:3503\u201310.","journal-title":"J Clin Oncol"},{"key":"1718_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bjh.16326","volume":"188","author":"H Huang","year":"2020","unstructured":"Huang H, Qin T, Xu Z, Shi Z, Li B, Pan L, et al. Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. Br J Haematol. 2020;188:796\u2013800.","journal-title":"Br J Haematol"},{"key":"1718_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"3","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, et al. NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3:922\u201333.","journal-title":"Blood Adv"},{"key":"1718_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","volume":"3","author":"SS Patel","year":"2019","unstructured":"Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv. 2019;3:1540\u201345.","journal-title":"Blood Adv"},{"key":"1718_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ajcp\/aqx043","volume":"148","author":"E Margolskee","year":"2017","unstructured":"Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, et al. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017;148:49\u201357.","journal-title":"Am J Clin Pathol"},{"key":"1718_CR20","doi-asserted-by":"publisher","first-page":"E631","DOI":"10.1002\/ajh.24867","volume":"92","author":"MF van Spronsen","year":"2017","unstructured":"van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, et al. Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. Am J Hematol. 2017;92:E631\u201334.","journal-title":"Am J Hematol"},{"key":"1718_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl J Med. 2011;365:1384\u201395.","journal-title":"N. Engl J Med"},{"key":"1718_CR22","doi-asserted-by":"publisher","first-page":"v5467","DOI":"10.1126\/scitranslmed.aav5467","volume":"11","author":"S Bondu","year":"2019","unstructured":"Bondu S, Alary AS, Lefevre C, Houy A, Jung G, Lefebvre T, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med. 2019;11:v5467.","journal-title":"Sci Transl Med"},{"key":"1718_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06063-x","volume":"9","author":"Y Shiozawa","year":"2018","unstructured":"Shiozawa Y, Malcovati L, Galli A, Sato-Otsubo A, Kataoka K, Sato Y, et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018;9:3649.","journal-title":"Nat Commun"},{"key":"1718_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, J\u00e4dersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233\u201341.","journal-title":"Blood."},{"key":"1718_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157\u201370.","journal-title":"Blood."},{"key":"1718_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N. Engl J Med. 2020;382:140\u201351.","journal-title":"N. Engl J Med"},{"key":"1718_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/modpathol.2013.187","volume":"27","author":"B Fu","year":"2014","unstructured":"Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ, et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014;27:681\u201389.","journal-title":"Mod Pathol"},{"key":"1718_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2405030","volume":"22","author":"G Buesche","year":"2008","unstructured":"Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22:313\u201322.","journal-title":"Leukemia."},{"key":"1718_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","volume":"27","author":"PM Della","year":"2009","unstructured":"Della PM, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754\u201362.","journal-title":"J Clin Oncol"},{"key":"1718_CR30","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41375-019-0457-1","volume":"33","author":"E Bono","year":"2019","unstructured":"Bono E, McLornan D, Travaglino E, Gandhi S, Gall\u00ec A, Khan AA, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33:2495\u2013505.","journal-title":"Leukemia."},{"key":"1718_CR31","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41375-022-01592-3","volume":"36","author":"G Calabretto","year":"2022","unstructured":"Calabretto G, Attardi E, Teramo A, Trimarco V, Carraro S, Mossuto S, et al. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia. 2022;36:1947\u201350.","journal-title":"Leukemia."},{"key":"1718_CR32","doi-asserted-by":"publisher","first-page":"63177","DOI":"10.18632\/oncotarget.11050","volume":"7","author":"CY Yao","year":"2016","unstructured":"Yao CY, Hou HA, Lin TY, Lin CC, Chou WC, Tseng MH, et al. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget. 2016;7:63177\u201388.","journal-title":"Oncotarget."},{"key":"1718_CR33","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2015.130112","volume":"100","author":"A Nazha","year":"2015","unstructured":"Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway HE, Patel BJ, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100:e434\u201337.","journal-title":"Haematologica."},{"key":"1718_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3324\/haematol.13755","volume":"94","author":"JM Bennett","year":"2009","unstructured":"Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264\u201368.","journal-title":"Haematologica."},{"key":"1718_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.leukres.2012.09.021","volume":"37","author":"A Maassen","year":"2013","unstructured":"Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, et al. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res. 2013;37:64\u201370.","journal-title":"Leuk Res"},{"key":"1718_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00277-014-2252-4","volume":"94","author":"P Font","year":"2015","unstructured":"Font P, Loscertales J, Soto C, Ricard P, Novas CM, Mart\u00edn-Clavero E, et al. Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. Ann Hematol. 2015;94:565\u201373.","journal-title":"Ann Hematol"},{"key":"1718_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.leu.2404571","volume":"21","author":"A Matsuda","year":"2007","unstructured":"Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia. 2007;21:678\u201386.","journal-title":"Leukemia."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:05:18Z","timestamp":1669795518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01718-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to NexImmune Inc. Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}